RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market.
RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
About RBC Capital coverage
This page surfaces every story mentioning RBC Capital across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
What you see
What it tells you
Story count
Number of distinct stories where RBC Capital was a primary or referenced actor.
Recency clustering
Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distribution
Aggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche links
When the same entity surfaces in our sibling networks, we link to those views to enrich context.